argenx (ARGX) News Today $591.82 +17.28 (+3.01%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Les actions d'argenx voient leur objectif de cours relevé par Raymond James, la recommandation "Achat Fort" maintenueNovember 21 at 5:28 AM | fr.investing.comArgenx to continue development of efgartigimod subcutaneousNovember 21 at 5:28 AM | markets.businessinsider.comPositive Clinical Trial Results and Market Position Strengthen Buy Rating for Argenx SENovember 21 at 5:28 AM | markets.businessinsider.comJennison Associates LLC Has $129 Million Stock Position in argenx SE (NASDAQ:ARGX)Jennison Associates LLC grew its stake in argenx SE (NASDAQ:ARGX - Free Report) by 0.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 237,966 shares of the company's stock after buying an additional 1,528 shares durinNovember 20 at 7:37 AM | marketbeat.comargenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesNovember 20 at 1:00 AM | globenewswire.comFirst Turn Management LLC Sells 25,538 Shares of argenx SE (NASDAQ:ARGX)First Turn Management LLC lowered its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 31.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,440 shares of the company's stock after selling 25,November 19 at 6:15 AM | marketbeat.comMorgan Stanley Remains a Buy on Argenx Se (ARGX)November 19 at 2:08 AM | markets.businessinsider.comIs argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?November 18 at 6:50 PM | uk.finance.yahoo.comargenx SE (NASDAQ:ARGX) Shares Acquired by Janney Montgomery Scott LLCJanney Montgomery Scott LLC increased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 201.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,072 shares of the company's stock after buying an additional 1,384 shares during the period. Janney MontgoNovember 16, 2024 | marketbeat.comargenx (NASDAQ:ARGX) Upgraded by Wolfe Research to "Outperform" RatingNovember 16, 2024 | americanbankingnews.comargenx (NASDAQ:ARGX) Shares Gap Down - Here's What Happenedargenx (NASDAQ:ARGX) Shares Gap Down - Time to Sell?November 15, 2024 | marketbeat.comargenx SE (NASDAQ:ARGX) Shares Bought by Simplify Asset Management Inc.Simplify Asset Management Inc. raised its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 64.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,419 shares of the company's stock after acquiring an additional 944 shares during the period. Simplify AsseNovember 15, 2024 | marketbeat.comArgenx upgraded to Outperform from Peer Perform at Wolfe ResearchNovember 13, 2024 | markets.businessinsider.comArgenx and Zai Lab’s CIDP Drug Approved in ChinaNovember 12, 2024 | markets.businessinsider.comArgenx upgraded at Wolfe on myasthenia gravis dominanceNovember 12, 2024 | seekingalpha.comargenx (NASDAQ:ARGX) Upgraded by Wolfe Research to Outperform RatingWolfe Research upgraded argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price for the company in a report on Tuesday.November 12, 2024 | marketbeat.comCrossmark Global Holdings Inc. Buys 4,741 Shares of argenx SE (NASDAQ:ARGX)Crossmark Global Holdings Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 100.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,462 shares of the company's stock after buying an additional 4,741 shares during the periNovember 12, 2024 | marketbeat.comZai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNovember 11, 2024 | businesswire.comargenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaNovember 11, 2024 | globenewswire.comTimesSquare Capital Management LLC Acquires 8,840 Shares of argenx SE (NASDAQ:ARGX)TimesSquare Capital Management LLC boosted its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,490 shares of the company's stock after acNovember 10, 2024 | marketbeat.comargenx SE (NASDAQ:ARGX) Stake Reduced by Fiera Capital CorpFiera Capital Corp reduced its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 4.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,353 shares of the company's stock after selling 7,242 shareNovember 8, 2024 | marketbeat.comArgenx’s Efgartigimod: Promising Potential in Myositis Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comScotiabank upgrades Argenx on Vyvgart upside, pipeline optionalityNovember 5, 2024 | markets.businessinsider.comAlphaCentric Advisors LLC Has $2.44 Million Stock Holdings in argenx SE (NASDAQ:ARGX)AlphaCentric Advisors LLC cut its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 37.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,500 shares of the company's stock after selling 2,750 shares during the period. argenx comprises approximately 1.8November 5, 2024 | marketbeat.comargenx (NASDAQ:ARGX) Rating Increased to Sector Outperform at ScotiabankScotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and set a $715.00 price target for the company in a research note on Tuesday.November 5, 2024 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Argenx Se (ARGX)November 5, 2024 | markets.businessinsider.comargenx to Participate at Upcoming Investor ConferencesNovember 5, 2024 | globenewswire.comArgenx price target raised to EUR 525 from EUR 500 at Deutsche BankNovember 4, 2024 | markets.businessinsider.comargenx (NASDAQ:ARGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJPMorgan Chase & Co. raised their target price on shares of argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a report on Monday.November 4, 2024 | marketbeat.comNvwm LLC Takes $533,000 Position in argenx SE (NASDAQ:ARGX)Nvwm LLC bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 984 shares of the company's stock, valued at approximately $533,000. A numberNovember 4, 2024 | marketbeat.comWedbush Weighs in on argenx's Q1 Earnings (NASDAQ:ARGX)argenx SE (NASDAQ:ARGX - Free Report) - Equities research analysts at Wedbush lifted their Q1 2025 EPS estimates for argenx in a research note issued to investors on Thursday, October 31st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $1.91 per share for thNovember 4, 2024 | marketbeat.comArgenx Se: Strong Market Penetration and Pipeline Expansion Support Buy RatingNovember 3, 2024 | markets.businessinsider.comargenx SE (NASDAQ:ARGX) Given Average Recommendation of "Moderate Buy" by Analystsargenx SE (NASDAQ:ARGX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and oneNovember 3, 2024 | marketbeat.comArgenx’s Strong Financials and Strategic Growth Drive Buy RatingNovember 2, 2024 | markets.businessinsider.comArgenx price target raised to $639 from $547 at Wells FargoNovember 2, 2024 | markets.businessinsider.comArgenx price target raised to $660 from $540 at TruistNovember 2, 2024 | finance.yahoo.comargenx (NASDAQ:ARGX) Cut to Hold at Baird R WBaird R W lowered shares of argenx from a "strong-buy" rating to a "hold" rating in a report on Friday.November 2, 2024 | marketbeat.comargenx SE (NASDAQ:ARGX) Shares Sold by New York State Common Retirement FundNew York State Common Retirement Fund reduced its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 12.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,534 shares of the company's stock after selling 15,November 2, 2024 | marketbeat.comargenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ChallengesNovember 2, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Cigna (CI)November 2, 2024 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Argenx Se (ARGX)November 1, 2024 | markets.businessinsider.comargenx downgraded at Baird as shares get priceyNovember 1, 2024 | msn.comArgenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'November 1, 2024 | benzinga.comargenx SE (NASDAQ:ARGX) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comOppenheimer Reaffirms Their Buy Rating on Argenx Se (ARGX)November 1, 2024 | markets.businessinsider.comGuggenheim Increases argenx (NASDAQ:ARGX) Price Target to $665.00Guggenheim raised their price objective on shares of argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comargenx (NASDAQ:ARGX) Releases Earnings Results, Beats Expectations By $1.29 EPSargenx (NASDAQ:ARGX - Get Free Report) posted its earnings results on Thursday. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same period last year, the firm earned ($1.25) earnings per share.November 1, 2024 | marketbeat.comargenx (NASDAQ:ARGX) Rating Lowered to "Neutral" at Robert W. BairdRobert W. Baird cut argenx from an "outperform" rating to a "neutral" rating and increased their price target for the stock from $515.00 to $650.00 in a research note on Friday.November 1, 2024 | marketbeat.comargenx (NASDAQ:ARGX) Stock Rating Upgraded by William BlairWilliam Blair upgraded argenx from a "market perform" rating to an "outperform" rating in a research report on Friday.November 1, 2024 | marketbeat.comArgenx SE’s Strong Q3 Results and Future OutlookOctober 31, 2024 | markets.businessinsider.com Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin ARGX Media Mentions By Week ARGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARGX News Sentiment▼0.940.46▲Average Medical News Sentiment ARGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARGX Articles This Week▼108▲ARGX Articles Average Week Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GILD News BNTX News BIIB News MRNA News NBIX News PCVX News TECH News EXEL News RVMD News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARGX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARGX Stock Alerts